Supplementary Data Tables S1-S4 from Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events among patients remaining on study for at least 3 months. Table S4 shows the proportion of patients receiving stereotactic body radiation therapy to all RECIST target lesions and all clinically or radiographically apparent metastases by response category.
Authors: Corey C. Foster, Gini F. Fleming, Theodore G. Karrison, Chih-Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blase N. Polite, Olwen M. Hahn, Peter H. O'Donnell, Everett E. Vokes, Hedy L. Kindler, Robyn Hseu, Linda A. Janisch, Julia Dai, Mark D. Hoffman, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361890260